BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121:589-597. [PMID: 25312765 DOI: 10.1002/cncr.29099] [Cited by in Crossref: 337] [Cited by in F6Publishing: 301] [Article Influence: 48.1] [Reference Citation Analysis]
Number Citing Articles
1 Zhai H, Li D, Feng Q, Qian X, Li L, Yao J. Pancreatic neuroendocrine tumours: Grade is superior to T, N, or M status in predicting outcome and selecting patients for chemotherapy:A retrospective cohort study in the SEER database. Int J Surg 2019;66:103-9. [PMID: 30872175 DOI: 10.1016/j.ijsu.2019.03.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
2 Cuthbertson DJ, Barriuso J, Lamarca A, Manoharan P, Westwood T, Jaffa M, Fenwick SW, Nuttall C, Lalloo F, Prachalias A, Pizanias M, Wieshmann H, McNamara MG, Hubner R, Srirajaskanthan R, Vivian G, Ramage J, Weickert MO, Pritchard DM, Vinjamuri S, Valle J, Yip VS. The Impact of 68Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours. Front Endocrinol (Lausanne) 2021;12:654975. [PMID: 34163434 DOI: 10.3389/fendo.2021.654975] [Reference Citation Analysis]
3 Zhou H, Zhang Y, Wei X, Yang K, Tan W, Qiu Z, Li S, Chen Q, Song Y, Gao S. Racial disparities in pancreatic neuroendocrine tumors survival: a SEER study. Cancer Med 2017;6:2745-56. [PMID: 28980417 DOI: 10.1002/cam4.1220] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
4 Alwan H, La Rosa S, Andreas Kopp P, Germann S, Maspoli-Conconi M, Sempoux C, Bulliard JL. Incidence trends of lung and gastroenteropancreatic neuroendocrine neoplasms in Switzerland. Cancer Med 2020;9:9454-61. [PMID: 33078908 DOI: 10.1002/cam4.3524] [Reference Citation Analysis]
5 Pollock RF, Brennan VK, Peters R, Paprottka PM. Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis. Expert Rev Anticancer Ther 2020;20:997-1009. [PMID: 32930618 DOI: 10.1080/14737140.2020.1814748] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 VanDerslice J, Taddie MC, Curtin K, Miller C, Yu Z, Hemmert R, Cannon-Albright LA, Neklason DW. Early life exposures associated with risk of small intestinal neuroendocrine tumors. PLoS One 2020;15:e0231991. [PMID: 32324813 DOI: 10.1371/journal.pone.0231991] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 VandenBussche CJ, Allison DB, Graham MK, Charu V, Lennon AM, Wolfgang CL, Hruban RH, Heaphy CM. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors. Cancer Cytopathol 2017;125:544-51. [PMID: 28371511 DOI: 10.1002/cncy.21857] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
8 Hallet J, Coburn NG, Singh S, Beyfuss K, Koujanian S, Liu N, Law CHL. Access to care and outcomes for neuroendocrine tumours: does socioeconomic status matter? Curr Oncol 2018;25:e356-64. [PMID: 30464685 DOI: 10.3747/co.35.3930] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Lee MR, Harris C, Baeg KJ, Aronson A, Wisnivesky JP, Kim MK. Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States. Clin Gastroenterol Hepatol. 2018;. [PMID: 30580091 DOI: 10.1016/j.cgh.2018.12.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
10 Kelgiorgi D, Dervenis C. Pancreatic neuroendocrine tumors: the basics, the gray zone, and the target. F1000Res 2017;6:663. [PMID: 28529726 DOI: 10.12688/f1000research.10188.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
11 Levy S, van Veenendaal LM, Korse CM, Breekveldt ECH, Verbeek WHM, Vriens MR, Kuhlmann KFD, van den Berg JG, Valk GD, Tesselaar MET. Survival in Patients with Neuroendocrine Tumours of the Small Intestine: Nomogram Validation and Predictors of Survival. J Clin Med 2020;9:E2502. [PMID: 32756529 DOI: 10.3390/jcm9082502] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Darbà J, Marsà A. Exploring the current status of neuroendocrine tumours: a population-based analysis of epidemiology, management and use of resources. BMC Cancer 2019;19:1226. [PMID: 31842791 DOI: 10.1186/s12885-019-6412-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
13 Okubo Y, Yokose T, Motohashi O, Miyagi Y, Yoshioka E, Suzuki M, Washimi K, Kawachi K, Nito M, Nemoto T, Shibuya K, Kameda Y. Duodenal Rare Neuroendocrine Tumor: Clinicopathological Characteristics of Patients with Gangliocytic Paraganglioma. Gastroenterol Res Pract. 2016;2016:5257312. [PMID: 28096810 DOI: 10.1155/2016/5257312] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
14 Klemm N, Lu-Cleary D, Chahal D, Trasolini R, Lam E, Donnellan F. Endoscopic Management of Diminutive Duodenal Neuroendocrine Tumors. J Gastrointest Cancer 2021;52:448-53. [PMID: 33471257 DOI: 10.1007/s12029-020-00577-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Wyld D, Moore J, Tran N, Youl P. Incidence, survival and stage at diagnosis of small intestinal neuroendocrine tumours in Queensland, Australia, 2001-2015. Asia Pac J Clin Oncol 2021;17:350-8. [PMID: 33567164 DOI: 10.1111/ajco.13503] [Reference Citation Analysis]
16 Mullangi S, Lekkala MR, Raghu Subramanian C, Nemer O, Singh J, Kichloo A, Moftakhar B. Incidental Finding of Squamous Cell Carcinoma on a 68Ga-DOTATATE PET Scan. J Investig Med High Impact Case Rep 2021;9:23247096211035232. [PMID: 34311624 DOI: 10.1177/23247096211035232] [Reference Citation Analysis]
17 Young K, Starling N, Sadanandam A. The molecular biology of pancreatic neuroendocrine neoplasms: Challenges and translational opportunities. Semin Cancer Biol. 2020;61:132-138. [PMID: 31577961 DOI: 10.1016/j.semcancer.2019.09.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Joish VN, Perez-olle R, Lapuerta P, Dharba S, Zacks J. Burden of Carcinoid Heart Disease in Patients With Carcinoid Syndrome Initiating Somatostatin Analogues. Clinical Therapeutics 2019;41:1716-1723.e2. [DOI: 10.1016/j.clinthera.2019.06.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, Bailey DL, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan A, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, Wyld D, Segelov E; Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) Follow-up Working Group. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. JAMA Oncol. 2018;4:1597-1604. [PMID: 30054622 DOI: 10.1001/jamaoncol.2018.2428] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 15.5] [Reference Citation Analysis]
20 Werner RA, Bengel FM, Derlin T. [Theranostics and hybrid imaging for somatostatin receptor-expressing tumors]. Radiologe. 2020;60:413-420. [PMID: 32052116 DOI: 10.1007/s00117-020-00652-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Masters A, Nutt D. A Plutocratic Proposal: an ethical way for rich patients to pay for a place on a clinical trial. J Med Ethics 2017;43:730-6. [PMID: 28588147 DOI: 10.1136/medethics-2016-104050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
22 Neshandar Asli I, Norouzi G. Incidental Finding of Benign Trichilemmal Cysts on 99mTc-Octreotide Scan. Clin Nucl Med 2019;44:834-5. [PMID: 31306209 DOI: 10.1097/RLU.0000000000002737] [Reference Citation Analysis]
23 Scott AT, Howe JR. Management of Small Bowel Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:223-41. [PMID: 32151357 DOI: 10.1016/j.soc.2019.11.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
24 Larouche V, Akirov A, Thain E, Kim RH, Ezzat S. Co-occurrence of breast cancer and neuroendocrine tumours: New genetic insights beyond Multiple Endocrine Neoplasia syndromes. Endocrinol Diabetes Metab 2019;2:e00092. [PMID: 31592449 DOI: 10.1002/edm2.92] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
25 Zhong Q, Chen QY, Xie JW, Wang JB, Lin JX, Lu J, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Li P, Zheng CH, Huang CM. Incidence trend and conditional survival estimates of gastroenteropancreatic neuroendocrine tumors: A large population-based study. Cancer Med. 2018;7:3521-3533. [PMID: 29873204 DOI: 10.1002/cam4.1598] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
26 van Treijen MJC, Korse CM, van Leeuwaarde RS, Saveur LJ, Vriens MR, Verbeek WHM, Tesselaar MET, Valk GD. Blood Transcript Profiling for the Detection of Neuroendocrine Tumors: Results of a Large Independent Validation Study. Front Endocrinol (Lausanne) 2018;9:740. [PMID: 30564197 DOI: 10.3389/fendo.2018.00740] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
27 Younan G. Pancreas Solid Tumors. Surg Clin North Am 2020;100:565-80. [PMID: 32402301 DOI: 10.1016/j.suc.2020.02.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Naraev BG, Halland M, Halperin DM, Purvis AJ, OʼDorisio TM, Halfdanarson TR. Management of Diarrhea in Patients With Carcinoid Syndrome. Pancreas 2019;48:961-72. [PMID: 31425482 DOI: 10.1097/MPA.0000000000001384] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
29 Custodio A, Jimenez-Fonseca P, Carmona-Bayonas A, Gomez MJ, Del Olmo-García MI, Lorenzo I, Díaz JÁ, Canal N, De la Cruz G, Villabona C. Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study. Clin Transl Oncol 2021;23:2046-56. [PMID: 34109562 DOI: 10.1007/s12094-021-02608-7] [Reference Citation Analysis]
30 Cukier M, Vergara R, Mendez-Rios JD, Castillo O, Barrera I, Tello E, El Achtar O, Loo Y, Tapia H, Perez G, Peña M. Neuroendocrine tumors in Panama: A nationwide database analysis. Mol Clin Oncol 2021;15:157. [PMID: 34178328 DOI: 10.3892/mco.2021.2319] [Reference Citation Analysis]
31 Chen X, Li B, Wang S, Yang B, Zhu L, Ma S, Wu J, He Q, Zhao J, Zheng Z, Li S, Wang T, Liang L. Efficacy and safety of endoscopic submucosal dissection for gastrointestinal neuroendocrine tumors: a 10-year data analysis of Northern China. Scandinavian Journal of Gastroenterology 2019;54:384-9. [DOI: 10.1080/00365521.2019.1588367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Sistani G, Sutherland DEK, Mujoomdar A, Wiseman DP, Khatami A, Tsvetkova E, Reid RH, Laidley DT. Efficacy of 177Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study. Curr Oncol 2020;28:115-27. [PMID: 33622997 DOI: 10.3390/curroncol28010015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
33 Samsom KG, van Veenendaal LM, Valk GD, Vriens MR, Tesselaar MET, van den Berg JG. Molecular prognostic factors in small-intestinal neuroendocrine tumours. Endocr Connect 2019;8:906-22. [PMID: 31189127 DOI: 10.1530/EC-19-0206] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
34 Zhang J, Peng CS, Tian YH. Primary site surgery for elderly patients with distant metastatic pancreatic neuroendocrine tumor: to do or not to do? Clin Interv Aging 2019;14:1419-32. [PMID: 31496669 DOI: 10.2147/CIA.S209428] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Li G, Tian ML, Bing YT, Yuan CH, Xiu DR. Impact of a Prior Nonpancreatic Malignancy on Survival Outcomes of Patients With Stage IV Pancreatic Neuroendocrine Tumor: A Population-Based and Propensity Score Matching Study. Pancreas 2020;49:1090-8. [PMID: 32833943 DOI: 10.1097/MPA.0000000000001630] [Reference Citation Analysis]
36 Larghi A, Rizzatti G, Rimbaş M, Crino SF, Gasbarrini A, Costamagna G. EUS-guided radiofrequency ablation as an alternative to surgery for pancreatic neuroendocrine neoplasms: Who should we treat? Endosc Ultrasound 2019;8:220-6. [PMID: 31249164 DOI: 10.4103/eus.eus_28_19] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
37 do Amor Divino PH, Marchetti KR, Almeida MQ, Riechelmann RP. Functional pancreatic neuroendocrine tumour causing Cushing's syndrome: the effect of chemotherapy on clinical symptoms. Ecancermedicalscience 2017;11:773. [PMID: 29104610 DOI: 10.3332/ecancer.2017.773] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Leyden S, Kolarova T, Bouvier C, Caplin M, Conroy S, Davies P, Dureja S, Falconi M, Ferolla P, Fisher G, Goldstein G, Hicks RJ, Lawrence B, Majima Y, Metz DC, O'Toole D, Ruszniewski P, Wiedenmann B, Hollander R; International Neuroendocrine Cancer Alliance (INCA). Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals. Int J Cancer 2020;146:1316-23. [PMID: 31509608 DOI: 10.1002/ijc.32678] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
39 Contractor T, Kobayashi S, da Silva E, Clausen R, Chan C, Vosburgh E, Tang LH, Levine AJ, Harris CR. Sexual dimorphism of liver metastasis by murine pancreatic neuroendocrine tumors is affected by expression of complement C5. Oncotarget 2016;7:30585-96. [PMID: 27105526 DOI: 10.18632/oncotarget.8874] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
40 Forero Molina MA, Garcia E, Gonzalez-Devia D, García-Duperly R, Vera A. A 17-year-old male with a Small Bowel Neuroendocrine Tumor: flushing differential diagnosis. World Allergy Organ J 2017;10:30. [PMID: 28904734 DOI: 10.1186/s40413-017-0161-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Chan DL, Segelov E, Singh S. Everolimus in the management of metastatic neuroendocrine tumours. Therap Adv Gastroenterol. 2017;10:132-141. [PMID: 28286565 DOI: 10.1177/1756283x16674660] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 4.2] [Reference Citation Analysis]
42 Gudmundsdottir H, Möller PH, Jonasson JG, Björnsson ES. Gastroenteropancreatic neuroendocrine tumors in Iceland: a population-based study. Scand J Gastroenterol 2019;54:69-75. [PMID: 30638086 DOI: 10.1080/00365521.2018.1553061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
43 Gulpinar B, Peker E, Soydal C, Araz M, Elhan AH. Can we differentiate histologic subtypes of neuroendocrine tumour liver metastases at a single phase contrast-enhanced CT-correlation with Ga-68 DOTATATE PET/CT findings. Br J Radiol 2020;93:20190735. [PMID: 31922897 DOI: 10.1259/bjr.20190735] [Reference Citation Analysis]
44 Forner D, Cho P, Bullock M, Rayson D, Taylor SM, Hart RD, Trites JR, Rigby MH. Report of metastatic ileal neuroendocrine tumor to the submandibular gland. Int J Surg Case Rep 2018;53:1-4. [PMID: 30366169 DOI: 10.1016/j.ijscr.2018.10.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Ruzzenente A, Bagante F, Bertuzzo F, Aldrighetti L, Campagnaro T, Ercolani G, Conci S, Giuliante F, Dore A, Ferrero A, Torzilli G, Grazi GL, Ratti F, Cucchetti A, De Rose AM, Russolillo N, Cimino M, Perri P, Guglielmi A, Iacono C. Liver Resection for Neuroendocrine Tumor Liver Metastases Within Milan Criteria for Liver Transplantation. J Gastrointest Surg 2019;23:93-100. [PMID: 30242647 DOI: 10.1007/s11605-018-3973-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
46 Soldath P, Binderup T, Kjær A, Federspiel B, Langer SW, Knigge U, Petersen RH. Long-term survival and recurrence after resection of bronchopulmonary carcinoids: A single-center cohort study of 236 patients. Lung Cancer 2021;156:109-16. [PMID: 33940543 DOI: 10.1016/j.lungcan.2021.04.010] [Reference Citation Analysis]
47 Isenberg-Grzeda E, MacGregor M, Bergel A, Eagle S, Espi Forcen F, Mehta R, Matsoukas K, Wills J, Reidy-Lagunes D, Alici Y. Antidepressants appear safe in patients with carcinoid tumor: Results of a retrospective review. Eur J Surg Oncol 2018;44:744-9. [PMID: 29622373 DOI: 10.1016/j.ejso.2018.03.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
48 Ge W, Zhou D, Zhu L, Song W, Wang W. Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors. J Cancer 2018;9:4783-90. [PMID: 30588264 DOI: 10.7150/jca.25908] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
49 Scott AT, Weitz M, Breheny PJ, Ear PH, Darbro B, Brown BJ, Braun TA, Li G, Umesalma S, Kaemmer CA, Maharjan CK, Quelle DE, Bellizzi AM, Chandrasekharan C, Dillon JS, O'Dorisio TM, Howe JR. Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors. Clin Cancer Res 2020;26:2011-21. [PMID: 31937620 DOI: 10.1158/1078-0432.CCR-19-2884] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
50 Iyer RV, Konda B, Fountzilas C, Mukherjee S, Owen D, Attwood K, Wang C, Maguire O, Minderman H, Suffren SA, Hicks K, Wilton J, Bies R, Casucci D, Reidy-Lagunes D, Shah M. Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors. Cancer 2020;126:3689-97. [PMID: 32525561 DOI: 10.1002/cncr.32994] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
51 Reed CT, Duma N, Halfdanarson T, Buckner J. Primary neuroendocrine carcinoma of the brain. BMJ Case Rep 2019;12:e230582. [PMID: 31537610 DOI: 10.1136/bcr-2019-230582] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
52 Chan DL, Cheung M, Earle CC, Coburn N, Mittmann N, Rahman F, Liu N, Singh S. Are We Choosing Surveillance Imaging in Gastric and Pancreatic Cancers Wisely? A Population-Based Study. J Gastrointest Cancer 2020;51:189-95. [PMID: 30972631 DOI: 10.1007/s12029-019-00235-8] [Reference Citation Analysis]
53 Watzka FM, Meyer F, Staubitz JI, Fottner C, Schad A, Lang H, Musholt TJ. Prognostic Assessment of Non-functioning Neuroendocrine Pancreatic Neoplasms as a Basis for Risk-Adapted Resection Strategies. World J Surg 2020;44:594-603. [PMID: 31605171 DOI: 10.1007/s00268-019-05220-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
54 Chan MY, Ma KW, Chan A. Surgical management of neuroendocrine tumor-associated liver metastases: a review. Gland Surg 2018;7:28-35. [PMID: 29629317 DOI: 10.21037/gs.2017.11.16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
55 Köseoğlu H, Duzenli T, Sezikli M. Gastric neuroendocrine neoplasms: A review. World J Clin Cases 2021; 9(27): 7973-7985 [PMID: 34621854 DOI: 10.12998/wjcc.v9.i27.7973] [Reference Citation Analysis]
56 Jeune F, Taibi A, Gaujoux S. Update on the Surgical Treatment of Pancreatic Neuroendocrine Tumors. Scand J Surg. 2020;109:42-52. [PMID: 31975647 DOI: 10.1177/1457496919900417] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
57 Pinto MP, Muñoz Medel M, Carrillo D, Retamal IN, Bravo ML, Valenzuela Y, Nervi B, Sánchez C, Galindo H, Ibañez C, Peña J, Balmaceda C, Madrid J, Briones J, Torres J, Nilo F, Guarda FJ, Quintana JC, Orellana P, Mondaca S, Acevedo F, Vicentini D, Cordova-Delgado M, Owen GI, Garrido M. Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective. Horm Cancer 2019;10:3-10. [PMID: 30465145 DOI: 10.1007/s12672-018-0354-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
58 Waldum HL, Öberg K, Sørdal ØF, Sandvik AK, Gustafsson BI, Mjønes P, Fossmark R. Not only stem cells, but also mature cells, particularly neuroendocrine cells, may develop into tumours: time for a paradigm shift. Therap Adv Gastroenterol 2018;11:1756284818775054. [PMID: 29872453 DOI: 10.1177/1756284818775054] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
59 Chan DL, Singh S. Developments in the treatment of carcinoid syndrome - impact of telotristat. Ther Clin Risk Manag 2018;14:323-9. [PMID: 29503551 DOI: 10.2147/TCRM.S126143] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
60 Santos AP, Vinagre J, Soares P, Claro I, Sanches AC, Gomes L, Fernandes I, Catarino AL, Preto J, Pereira BD, Marques AP, Rodrigues F, Amaral C, Rocha G, Mellidez JC, Simões H, Lopes JM, Bugalho MJ; On behalf of the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism . Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism. Int J Endocrinol 2019;2019:4518742. [PMID: 31467527 DOI: 10.1155/2019/4518742] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Versluis JM, Brandsma D, van den Berg JG, Tesselaar M. Leptomeningeal metastases of a well-differentiated neuroendocrine tumour: a rare entity. BMJ Case Rep 2018;2018:bcr-2018-226557. [PMID: 30391925 DOI: 10.1136/bcr-2018-226557] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Aamir MA, Sahebally SM, Gyorffy H, Aremu M. Extra-pulmonary primary small-cell neuroendocrine carcinoma arising from the duodenum: rare tumor, unusual location. Clin Case Rep 2017;5:2117-20. [PMID: 29225868 DOI: 10.1002/ccr3.1267] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Gosain R, Ball S, Rana N, Groman A, Gage-Bouchard E, Dasari A, Mukherjee S. Geographic and demographic features of neuroendocrine tumors in the United States of America: A population-based study. Cancer 2020;126:792-9. [PMID: 31714595 DOI: 10.1002/cncr.32607] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
64 Moore MD, Finnerty B, Gray KD, Hoda R, Liu YF, Soong L, Beninato T, Rao R, Zarnegar R, Fahey TJ 3rd. Decreased UCHL1 expression as a cytologic biomarker for aggressive behavior in pancreatic neuroendocrine tumors. Surgery 2018;163:226-31. [PMID: 29150024 DOI: 10.1016/j.surg.2017.04.040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
65 White BE, Mujica-Mota R, Snowsill T, Gamper EM, Srirajaskanthan R, Ramage JK. Evaluating cost-effectiveness in the management of neuroendocrine neoplasms. Rev Endocr Metab Disord 2021;22:647-63. [PMID: 33155118 DOI: 10.1007/s11154-020-09608-y] [Reference Citation Analysis]
66 Tierney JF, Kosche C, Schadde E, Ali A, Virmani S, Pappas SG, Poirier J, Keutgen XM. 68Gallium-DOTATATE positron emission tomography-computed tomography (PET CT) changes management in a majority of patients with neuroendocrine tumors. Surgery 2019;165:178-85. [PMID: 30415869 DOI: 10.1016/j.surg.2018.03.030] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
67 Kulkarni RS, Anand AS, Parikh SK, Panchal HP, Patel AA, Mehta DP, Patel P. Clinical and epidemiological profile of neuroendocrine tumors: An experience from a regional cancer center from Western India. South Asian J Cancer 2019;8:198-202. [PMID: 31489301 DOI: 10.4103/sajc.sajc_364_18] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Man D, Wu J, Shen Z, Zhu X. Prognosis of patients with neuroendocrine tumor: a SEER database analysis. Cancer Manag Res. 2018;10:5629-5638. [PMID: 30519109 DOI: 10.2147/cmar.s174907] [Cited by in Crossref: 40] [Cited by in F6Publishing: 20] [Article Influence: 13.3] [Reference Citation Analysis]
69 Lyseng-Williamson KA. Telotristat Ethyl: A Review in Carcinoid Syndrome Diarrhoea. Drugs. 2018;78:941-950. [PMID: 29931594 DOI: 10.1007/s40265-018-0935-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
70 Iwaya H, Fukukura Y, Hashimoto S, Tanoue S, Kawahira M, Hinokuchi M, Fujita T, Komaki Y, Arima S, Sasaki F, Kanmura S, Higashi M, Tamada K, Ido A. Prognostic significance of extracellular volume fraction with equilibrium contrast-enhanced computed tomography for pancreatic neuroendocrine neoplasms. Pancreatology 2021;21:779-86. [PMID: 33714670 DOI: 10.1016/j.pan.2021.02.020] [Reference Citation Analysis]
71 Rossi RE, Invernizzi P, Mazzaferro V, Massironi S. Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis. United European Gastroenterol J 2020;8:140-7. [PMID: 32213066 DOI: 10.1177/2050640619890465] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Al-Ramadan A, Mortensen AC, Carlsson J, Nestor MV. Analysis of radiation effects in two irradiated tumor spheroid models. Oncol Lett 2018;15:3008-16. [PMID: 29435031 DOI: 10.3892/ol.2017.7716] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
73 Wang XY, Chai NL, Linghu EQ, Li HK, Zhai YQ, Feng XX, Zhang WG, Zou JL, Li LS, Xiang JY. Efficacy and safety of hybrid endoscopic submucosal dissection compared with endoscopic submucosal dissection for rectal neuroendocrine tumors and risk factors associated with incomplete endoscopic resection. Ann Transl Med 2020;8:368. [PMID: 32355812 DOI: 10.21037/atm.2020.02.25] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
74 Rindi G, Wiedenmann B. Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine. Nat Rev Endocrinol 2020;16:590-607. [PMID: 32839579 DOI: 10.1038/s41574-020-0391-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
75 Broder MS, Cai B, Chang E, Neary MP. Incidence and prevalence of neuroendocrine tumors of the lung: analysis of a US commercial insurance claims database. BMC Pulm Med 2018;18:135. [PMID: 30103725 DOI: 10.1186/s12890-018-0678-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
76 Zhang G, Wu B, Wang X, Li J. A competing-risks nomogram and recursive partitioning analysis for cause-specific mortality in patients with esophageal neuroendocrine carcinoma. Dis Esophagus. 2019;32:doy129. [PMID: 30715226 DOI: 10.1093/dote/doy129] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
77 Ma ZY, Gong YF, Zhuang HK, Zhou ZX, Huang SZ, Zou YP, Huang BW, Sun ZH, Zhang CZ, Tang YQ, Hou BH. Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management. World J Gastroenterol 2020; 26(19): 2305-2322 [PMID: 32476795 DOI: 10.3748/wjg.v26.i19.2305] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
78 Mirkin KA, Hollenbeak CS, Wong J. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm. Journal of Surgical Research 2017;211:206-14. [DOI: 10.1016/j.jss.2016.12.033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
79 Lewis A, Raoof M, Ituarte PHG, Williams J, Melstrom L, Li D, Lee B, Singh G. Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment. Ann Surg 2019;270:1131-7. [PMID: 29746336 DOI: 10.1097/SLA.0000000000002809] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 21.0] [Reference Citation Analysis]
80 Pu N, Habib JR, Bejjani M, Yin H, Nagai M, Chen J, Kinny-Köster B, Chen Q, Zhang J, Yu J, Wu W, Lou W. The effect of primary site, functional status and treatment modality on survival in gastroenteropancreatic neuroendocrine neoplasms with synchronous liver metastasis: a US population-based study. Ann Transl Med 2021;9:329. [PMID: 33708956 DOI: 10.21037/atm-20-5348] [Reference Citation Analysis]
81 Bruno W, Fornarini G, Ghiorzo P. Signs and genetics of rare cancer syndromes with gastroenterological features. World J Gastroenterol 2015; 21(30): 8985-8993 [PMID: 26290627 DOI: 10.3748/wjg.v21.i30.8985] [Reference Citation Analysis]
82 Crona J, Skogseid B. GEP- NETS UPDATE: Genetics of neuroendocrine tumors. Eur J Endocrinol. 2016;174:R275-R290. [PMID: 27165966 DOI: 10.1530/eje-15-0972] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 6.8] [Reference Citation Analysis]
83 Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med 2018;59:66-74. [PMID: 29025982 DOI: 10.2967/jnumed.117.202275] [Cited by in Crossref: 99] [Cited by in F6Publishing: 81] [Article Influence: 24.8] [Reference Citation Analysis]
84 Zheng Z, Chen C, Jiang L, Zhou X, Dai X, Song Y, Li Y. Incidence and risk factors of gastrointestinal neuroendocrine neoplasm metastasis in liver, lung, bone, and brain: A population-based study. Cancer Med. 2019;8:7288-7298. [PMID: 31609098 DOI: 10.1002/cam4.2567] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
85 Dasari A, Joish VN, Perez-Olle R, Dharba S, Balaji K, Halperin DM. Direct costs of carcinoid syndrome diarrhea among adults in the United States. World J Gastroenterol 2019; 25(47): 6857-6865 [PMID: 31885426 DOI: 10.3748/wjg.v25.i47.6857] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Sonbol MB, Saad AM, Gonzalez-Velez M, Starr J, Halfdanarson TR. Causes of Death After Neuroendocrine Tumors Diagnosis: A US Population-Based Analysis. Pancreas 2021;50:47-53. [PMID: 33370022 DOI: 10.1097/MPA.0000000000001723] [Reference Citation Analysis]
87 Vaghaiwalla T, Keutgen XM. Surgical Management of Pancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:243-52. [PMID: 32151358 DOI: 10.1016/j.soc.2019.11.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
88 Wetz C, Genseke P, Apostolova I, Furth C, Ghazzawi S, Rogasch JMM, Schatka I, Kreissl MC, Hofheinz F, Grosser OS, Amthauer H. The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [177Lu]-DOTATATE. PLoS One 2019;14:e0216781. [PMID: 31091247 DOI: 10.1371/journal.pone.0216781] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
89 Kooyker AI, Verbeek WH, van den Berg JG, Tesselaar ME, van Leerdam ME. Change in incidence, characteristics and management of colorectal neuroendocrine tumours in the Netherlands in the last decade. United European Gastroenterol J 2020;8:59-67. [PMID: 32213058 DOI: 10.1177/2050640619865113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
90 Liu B, Kudo A, Kinowaki Y, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Tanaka S, Akashi T, Tanabe M. A simple and practical index predicting the prognoses of the patients with well-differentiated pancreatic neuroendocrine neoplasms. J Gastroenterol 2019;54:819-28. [PMID: 30863885 DOI: 10.1007/s00535-019-01570-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
91 Sanli Y, Garg I, Kandathil A, Kendi T, Zanetti MJB, Kuyumcu S, Subramaniam RM. Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET/CT. AJR Am J Roentgenol 2018;211:267-77. [PMID: 29975116 DOI: 10.2214/AJR.18.19881] [Cited by in Crossref: 37] [Cited by in F6Publishing: 12] [Article Influence: 12.3] [Reference Citation Analysis]
92 Ramírez-Rentería C, Ferreira-Hermosillo A, Marrero-Rodríguez D, Taniguchi-Ponciano K, Melgar-Manzanilla V, Mercado M. An Update on Gastroenteropancreatic Neuroendocrine Neoplasms: From Mysteries to Paradigm Shifts. Arch Med Res 2020;51:765-76. [PMID: 32654882 DOI: 10.1016/j.arcmed.2020.06.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Hallet J, Davis LE, Mahar AL, Isenberg-grzeda E, Bubis LD, Myrehaug S, Zhao H, Beyfuss K, Moody L, Law CHL, Coburn NG. Symptom Burden at the End of Life for Neuroendocrine Tumors: An Analysis of 2579 Prospectively Collected Patient-Reported Outcomes. Ann Surg Oncol 2019;26:2711-21. [DOI: 10.1245/s10434-019-07441-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
94 Beesley VL, Burge M, Dumbrava M, Callum J, Neale RE, Wyld DK. Perceptions of care and patient-reported outcomes in people living with neuroendocrine tumours. Support Care Cancer 2018;26:3153-61. [DOI: 10.1007/s00520-018-4166-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
95 Scott AT, Howe JR. Evaluation and Management of Neuroendocrine Tumors of the Pancreas. Surg Clin North Am 2019;99:793-814. [PMID: 31255207 DOI: 10.1016/j.suc.2019.04.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
96 Broder MS, Cai B, Chang E, Neary MP, Papoyan E, Benson AB III. Real-World Treatment Patterns for Lung Neuroendocrine Tumors: A Claims Database Analysis. Oncology 2018;94:281-8. [PMID: 29510379 DOI: 10.1159/000486282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
97 Altieri B, Di Dato C, Martini C, Sciammarella C, Di Sarno A, Colao A, Faggiano A; NIKE Group. Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management. Cancers (Basel) 2019;11:E1332. [PMID: 31500357 DOI: 10.3390/cancers11091332] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
98 Heckert JM, Kipnis ST, Kumar S, Botterbusch S, Alderson A, Bennett B, Creamer C, Eads JR, Soulen MC, Pryma DA, Mankoff DA, Metz DC, Katona BW. Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.-Based Neuroendocrine Tumor Cohort. Oncologist 2020;25:572-8. [PMID: 32141667 DOI: 10.1634/theoncologist.2019-0743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
99 Hallet J, Law CH, Karanicolas PJ, Saskin R, Liu N, Singh S. Rural-urban disparities in incidence and outcomes of neuroendocrine tumors: A population-based analysis of 6271 cases. Cancer. 2015;121:2214-2221. [PMID: 25823667 DOI: 10.1002/cncr.29338] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
100 Jiménez-Fonseca P, Martín MN, Carmona-Bayonas A, Calvo A, Fernández-Mateos J, Redrado M, Capdevila J, Lago NM, Lacasta A, Muñarriz J, Segura Á, Fuster J, Barón F, Llanos M, Serrano R, Castillo A, Cruz Hernández JJ, Grande E. Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib. Oncotarget 2018;9:36894-905. [PMID: 30651923 DOI: 10.18632/oncotarget.26380] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
101 Versluis J, Valk G, van Rossum H, Tesselaar M. Non-islet cell tumour hypoglycaemia in a patient with a well-differentiated gastric neuroendocrine tumour. BMJ Case Rep 2019;12:e231069. [PMID: 31527214 DOI: 10.1136/bcr-2019-231069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
102 Rodriguez-Freixinos V, Capdevila J, Pavel M, Thawer A, Baudin E, O'Toole D, Herrmann K, Welin S, Grozinsky-Glasberg S, de Herder WW, Valle JW, Herman J, Kolarova T, Bouvier C, Falconi M, Ferone D, Singh S. Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. Eur J Cancer 2021;144:200-14. [PMID: 33370645 DOI: 10.1016/j.ejca.2020.11.037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
103 Helali M, Addeo P, Heimburger C, Detour J, Goichot B, Bachellier P, Namer IJ, Taïeb D, Imperiale A. Carbidopa-assisted 18F-fluorodihydroxyphenylalanine PET/CT for the localization and staging of non-functioning neuroendocrine pancreatic tumors. Ann Nucl Med 2016;30:659-68. [PMID: 27485404 DOI: 10.1007/s12149-016-1110-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
104 Samsom KG, Levy S, van Veenendaal LM, Roepman P, Kodach LL, Steeghs N, Valk GD, Wouter Dercksen M, Kuhlmann KFD, Verbeek WHM, Meijer GA, Tesselaar MET, van den Berg JG. Driver mutations occur frequently in metastases of well-differentiated small intestine neuroendocrine tumours. Histopathology 2021;78:556-66. [PMID: 32931025 DOI: 10.1111/his.14252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
105 Kotteas EA, Syrigos KN, Saif MW. Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors. Onco Targets Ther 2016;9:699-704. [PMID: 26929640 DOI: 10.2147/OTT.S72155] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
106 Gabriel M, Nilica B, Kaiser B, Virgolini IJ. Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy. J Nucl Med 2019;60:524-9. [PMID: 30115690 DOI: 10.2967/jnumed.118.215376] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
107 Burk KS, Lo GC, Gee MS, Sahani DV. Imaging and Screening of Pancreatic Cancer. Radiol Clin North Am 2017;55:1223-34. [PMID: 28991562 DOI: 10.1016/j.rcl.2017.06.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
108 Li G, Tian ML, Bing YT, Tao LY, Wang HY, Jiang B, Yuan CH, Xiu DR. Clinicopathological features and prognosis factors for survival in elderly patients with pancreatic neuroendocrine tumor: A STROBE-compliant article. Medicine (Baltimore) 2019;98:e14576. [PMID: 30882623 DOI: 10.1097/MD.0000000000014576] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
109 Martini C, Buxbaum S, Rodrigues M, Nilica B, Scarpa L, Holzner B, Virgolini I, Gamper EM. Quality of Life in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy: Information from a Monitoring Program in Clinical Routine. J Nucl Med. 2018;59:1566-1573. [PMID: 30042164 DOI: 10.2967/jnumed.117.204834] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
110 Hu Y, Ye Z, Wang F, Qin Y, Xu X, Yu X, Ji S. Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy. Front Endocrinol (Lausanne) 2021;12:679000. [PMID: 34093445 DOI: 10.3389/fendo.2021.679000] [Reference Citation Analysis]
111 Wyld D, Wan MH, Moore J, Dunn N, Youl P. Epidemiological trends of neuroendocrine tumours over three decades in Queensland, Australia. Cancer Epidemiology 2019;63:101598. [DOI: 10.1016/j.canep.2019.101598] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
112 Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017;3:1335-42. [PMID: 28448665 DOI: 10.1001/jamaoncol.2017.0589] [Cited by in Crossref: 967] [Cited by in F6Publishing: 891] [Article Influence: 241.8] [Reference Citation Analysis]
113 Mosenia A, Ward C, Yee A, Qorbani A, Corvera C. Multifocal pancreatic PPoma in the setting of MEN1: Case report and review of literature. Int J Surg Case Rep 2021;83:106008. [PMID: 34118524 DOI: 10.1016/j.ijscr.2021.106008] [Reference Citation Analysis]
114 Das S, Dasari A. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences? Curr Oncol Rep 2021;23:43. [PMID: 33719003 DOI: 10.1007/s11912-021-01029-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Gao B, Zhou D, Qian X, Jiang Y, Liu Z, Zhang W, Wang W. Number of Positive Lymph Nodes Is Superior to LNR and LODDS for Predicting the Prognosis of Pancreatic Neuroendocrine Neoplasms. Front Endocrinol (Lausanne) 2021;12:613755. [PMID: 33746899 DOI: 10.3389/fendo.2021.613755] [Reference Citation Analysis]
116 Barat M, Cottereau AS, Kedra A, Dermine S, Palmieri LJ, Coriat R, Dautry R, Tselikas L, Soyer P, Dohan A. The Role of Interventional Radiology for the Treatment of Hepatic Metastases from Neuroendocrine Tumor: An Updated Review. J Clin Med 2020;9:E2302. [PMID: 32698459 DOI: 10.3390/jcm9072302] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
117 Katona BW, Roccaro GA, Soulen MC, Yang YX, Bennett BJ, Riff BP, Glynn RA, Wild D, Nicolas GP, Pryma DA, Teitelbaum UR, Metz DC. Efficacy of Peptide Receptor Radionuclide Therapy in a United States-Based Cohort of Metastatic Neuroendocrine Tumor Patients: Single-Institution Retrospective Analysis. Pancreas 2017;46:1121-6. [PMID: 28902781 DOI: 10.1097/MPA.0000000000000919] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
118 Zhang MY, He D, Zhang S. Pancreatic neuroendocrine tumors G3 and pancreatic neuroendocrine carcinomas: Differences in basic biology and treatment. World J Gastrointest Oncol 2020; 12(7): 705-718 [PMID: 32864039 DOI: 10.4251/wjgo.v12.i7.705] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Zhou Y, Hou P, Zha KJ, Wang F, Zhou K, He W, Gao JB. Prognostic value of pretreatment contrast-enhanced computed tomography in esophageal neuroendocrine carcinoma: A multi-center follow-up study. World J Gastroenterol 2020; 26(31): 4680-4693 [PMID: 32884225 DOI: 10.3748/wjg.v26.i31.4680] [Reference Citation Analysis]
120 Yadav S, Sharma P, Zakalik D. Comparison of Demographics, Tumor Characteristics, and Survival Between Pancreatic Adenocarcinomas and Pancreatic Neuroendocrine Tumors: A Population-based Study. American Journal of Clinical Oncology 2018;41:485-91. [DOI: 10.1097/coc.0000000000000305] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 4.3] [Reference Citation Analysis]
121 Guccione L, Gough K, Drosdowsky A, Price T, Pavlakis N, Wyld D, Ransom D, Michael M, Schofield P. The unmet supportive care needs, quality of life, and care experiences of patients with functioning and non-functioning Neuroendocrine tumours (NETs) at early diagnosis. Patient Educ Couns 2021:S0738-3991(21)00335-9. [PMID: 34030927 DOI: 10.1016/j.pec.2021.05.006] [Reference Citation Analysis]
122 Chan DL, Singh S. Current Chemotherapy Use in Neuroendocrine Tumors. Endocrinol Metab Clin North Am 2018;47:603-14. [PMID: 30098718 DOI: 10.1016/j.ecl.2018.04.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
123 Löser A, Schwarzenböck SM, Heuschkel M, Willenberg HS, Krause BJ, Kurth J. Peptide receptor radionuclide therapy with 177Lu-DOTA-octreotate: dosimetry, nephrotoxicity, and the effect of hematological toxicity on survival. Nucl Med Commun 2018;39:236-46. [PMID: 29315138 DOI: 10.1097/MNM.0000000000000795] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
124 Keutgen XM, Schadde E, Pommier RF, Halfdanarson TR, Howe JR, Kebebew E. Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver. Semin Oncol 2018;45:232-5. [PMID: 30318110 DOI: 10.1053/j.seminoncol.2018.07.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
125 Eads JR. Poorly Differentiated Neuroendocrine Tumors. Hematology/Oncology Clinics of North America 2016;30:151-62. [DOI: 10.1016/j.hoc.2015.09.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
126 Chan DL, Ulaner GA, Pattison D, Wyld D, Ladwa R, Kirchner J, Li BT, Lai WV, Pavlakis N, Roach PJ, Bailey DL. Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker. J Nucl Med 2021;62:1278-84. [PMID: 33579809 DOI: 10.2967/jnumed.120.257659] [Reference Citation Analysis]
127 Eriksson J, Norlén O, Ögren M, Garmo H, Ihre-Lundgren C, Hellman P. Primary small intestinal neuroendocrine tumors are highly prevalent and often multiple before metastatic disease develops. Scand J Surg 2021;110:44-50. [PMID: 31587594 DOI: 10.1177/1457496919874484] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
128 Yu L, Wang J. T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances. J Cancer Res Clin Oncol. 2019;145:941-956. [PMID: 30798356 DOI: 10.1007/s00432-019-02867-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
129 Aburjania Z, Whitt JD, Jang S, Nadkarni DH, Chen H, Rose JB, Velu SE, Jaskula-Sztul R. Synthetic Makaluvamine Analogs Decrease c-Kit Expression and Are Cytotoxic to Neuroendocrine Tumor Cells. Molecules 2020;25:E4940. [PMID: 33114525 DOI: 10.3390/molecules25214940] [Reference Citation Analysis]
130 Chan DL, Dixon M, Law CHL, Koujanian S, Beyfuss KA, Singh S, Myrehaug S, Hallet J. Outcomes of Cytoreductive Surgery for Metastatic Low-Grade Neuroendocrine Tumors in the Setting of Extrahepatic Metastases. Ann Surg Oncol 2018;25:1768-74. [PMID: 29560571 DOI: 10.1245/s10434-018-6433-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
131 Guccione L, Gough K, Drosdowsky A, Fisher K, Price T, Pavlakis N, Khasraw M, Wyld D, Ransom D, Kong G, Rogers M, Leyden S, Leyden J, Michael M, Schofield P. Defining the Supportive Care Needs and Psychological Morbidity of Patients With Functioning Versus Nonfunctioning Neuroendocrine Tumors: Protocol for a Phase 1 Trial of a Nurse-Led Online and Phone-Based Intervention. JMIR Res Protoc 2019;8:e14361. [PMID: 31793892 DOI: 10.2196/14361] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
132 Woodhouse B, Pattison S, Segelov E, Singh S, Parker K, Kong G, Macdonald W, Wyld D, Meyer-Rochow G, Pavlakis N, Conroy S, Gordon V, Koea J, Kramer N, Michael M, Wakelin K, Asif T, Lo D, Price T, Lawrence B; Commonwealth Neuroendocrine Tumour Collaboration (CommNETs). Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care. J Clin Med 2019;8:E1455. [PMID: 31547431 DOI: 10.3390/jcm8091455] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
133 Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, Minter RM, Lairmore TC, Tseng JF, Zeh HJ, Libutti SK, Singh G, Lee JE, Hope TA, Kim MK, Menda Y, Halfdanarson TR, Chan JA, Pommier RF. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas. 2020;49:1-33. [PMID: 31856076 DOI: 10.1097/mpa.0000000000001454] [Cited by in Crossref: 56] [Cited by in F6Publishing: 23] [Article Influence: 56.0] [Reference Citation Analysis]
134 Rodriguez EF, Fite JJ, Chowsilpa S, Maleki Z. Insulinoma-associated protein 1 immunostaining on cytology specimens: an institutional experience. Hum Pathol 2019;85:128-35. [PMID: 30502379 DOI: 10.1016/j.humpath.2018.10.035] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
135 Benson III AB, Broder MS, Cai B, Chang E, Neary MP, Papoyan E. Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis. World J Gastroenterol 2017; 23(33): 6128-6136 [PMID: 28970728 DOI: 10.3748/wjg.v23.i33.6128] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
136 Dou D, Shi YF, Liu Q, Luo J, Liu JX, Liu M, Liu YY, Li YL, Qiu XD, Tan HY. Hsa-miR-202-3p, up-regulated in type 1 gastric neuroendocrine neoplasms, may target DUSP1World J Gastroenterol 2018; 24(5): 573-582 [PMID: 29434446 DOI: 10.3748/wjg.v24.i5.573] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
137 Desai GS, Pande P, Chhabra V, Shah RC, Jagannath P. Multimodality management, recurrence patterns, and long-term outcome of gastroenteropancreatic neuroendocrine neoplasms: Progress over 17 years. Indian J Gastroenterol 2019;38:399-410. [PMID: 31802438 DOI: 10.1007/s12664-019-00957-4] [Reference Citation Analysis]
138 Cloyd JM, Poultsides GA. Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management. World J Gastroenterol 2015; 21(32): 9512-9525 [PMID: 26327759 DOI: 10.3748/wjg.v21.i32.9512] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 56] [Article Influence: 10.5] [Reference Citation Analysis]
139 Berzaczy D, Giraudo C, Haug AR, Raderer M, Senn D, Karanikas G, Weber M, Mayerhoefer ME. Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients. Clin Nucl Med 2017;42:669-74. [PMID: 28682844 DOI: 10.1097/RLU.0000000000001753] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 10.3] [Reference Citation Analysis]
140 Mokhtar A, Arnason T, Gaston D, Huang WY, MacKenzie H, Al-Hazmi R, Vaninetti N, Tugwell B, Rayson D. ACTH-Secreting Neuroendocrine Carcinoma of the Cecum: Case Report and Review of the Literature. Clin Colorectal Cancer 2019;18:e163-70. [PMID: 30314823 DOI: 10.1016/j.clcc.2018.07.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
141 Lamberti G, Ceccarelli C, Brighi N, Maggio I, Santini D, Mosconi C, Ricci C, Biasco G, Campana D. Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors. Gastroenterol Res Pract 2017;2017:7872519. [PMID: 29213282 DOI: 10.1155/2017/7872519] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
142 Singh S, Chan DL. Small Bowel Neuroendocrine Tumors: Big Advances in the Land of Small Tumors. J Oncol Pract 2018;14:485-6. [PMID: 30096275 DOI: 10.1200/JOP.18.00392] [Reference Citation Analysis]
143 Segelov E, Chan D, Lawrence B, Pavlakis N, Kennecke HF, Jackson C, Law C, Singh S. Identifying and Prioritizing Gaps in Neuroendocrine Tumor Research: A Modified Delphi Process With Patients and Health Care Providers to Set the Research Action Plan for the Newly Formed Commonwealth Neuroendocrine Tumor Collaboration. J Glob Oncol 2017;3:380-8. [PMID: 28831446 DOI: 10.1200/JGO.2016.006916] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
144 Raphael MJ, Chan DL, Law C, Singh S. Principles of diagnosis and management of neuroendocrine tumours. CMAJ 2017;189:E398-404. [PMID: 28385820 DOI: 10.1503/cmaj.160771] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
145 Keck KJ, Choi A, Maxwell JE, Li G, O'Dorisio TM, Breheny P, Bellizzi AM, Howe JR. Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival. Ann Surg Oncol 2017;24:2206-12. [PMID: 28560597 DOI: 10.1245/s10434-017-5899-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
146 Dannoon SF, Alenezi SA, Elgazzar AH. The efficacy of the available peptide receptor radionuclide therapy for neuroendocrine tumors: a meta-analysis. Nuclear Medicine Communications 2017;38:1085-93. [DOI: 10.1097/mnm.0000000000000758] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
147 Giraldi L, Vecchioni A, Carioli G, Bilotta M, La Rosa S, Imperatori A, Volante M, Brizzi MP, Inzani F, Petrone G, Schinzari G, Bianchi A, Margaritora S, Alfieri S, La Vecchia C, Boccia S, Rindi G. Risk factors for pancreas and lung neuroendocrine neoplasms: a case-control study. Endocrine 2021;71:233-41. [PMID: 32869113 DOI: 10.1007/s12020-020-02464-5] [Reference Citation Analysis]
148 Ptasnuka M, Ozolins A, Narbuts Z, Truskovs A, Sperga M, Plaudis H. Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia. World J Surg 2020;44:585-93. [PMID: 31605174 DOI: 10.1007/s00268-019-05219-0] [Reference Citation Analysis]
149 Liu E, Paulson S, Gulati A, Freudman J, Grosh W, Kafer S, Wickremesinghe PC, Salem RR, Bodei L. Assessment of NETest Clinical Utility in a U.S. Registry-Based Study. Oncologist 2019;24:783-90. [PMID: 30158287 DOI: 10.1634/theoncologist.2017-0623] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
150 Calanchini M, Tadman M, Krogh J, Fabbri A, Grossman A, Shine B. Measurement of urinary 5-HIAA: correlation between spot versus 24-h urine collection. Endocr Connect 2019;8:1082-8. [PMID: 31265996 DOI: 10.1530/EC-19-0269] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
151 Low SK, Giannis D, Bahaie NS, Trong BLH, Moris D, Huy NT. Competing Mortality in Patients With Neuroendocrine Tumors. Am J Clin Oncol 2019;42:668-74. [PMID: 31343423 DOI: 10.1097/COC.0000000000000575] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
152 Pusceddu S, Vernieri C, Prinzi N, Torchio M, Coppa J, Antista M, Niger M, Milione M, Giacomelli L, Corti F, Prisciandaro M, Monteleone M, Colombo E, Di Bartolomeo M, de Braud F. The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence. Therap Adv Gastroenterol. 2020;13:1756284820927271. [PMID: 32821286 DOI: 10.1177/1756284820927271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
153 Lin E, Chen T, Little A, Holliday L, Roach P, Butler P, Hosking E, Bailey E, Elison B, Currow D. Safety and outcomes of 177 Lu-DOTATATE for neuroendocrine tumours: experience in New South Wales, Australia. Intern Med J 2019;49:1268-77. [PMID: 31062490 DOI: 10.1111/imj.14336] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
154 Roy AC, Wattchow D, Astill D, Singh S, Pendlebury S, Gormly K, Segelov E. Uncommon Anal Neoplasms. Surgical Oncology Clinics of North America 2017;26:143-61. [DOI: 10.1016/j.soc.2016.07.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
155 Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary M, Bergsland E. Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices. Med Oncol 2017;34:88. [PMID: 28393314 DOI: 10.1007/s12032-017-0927-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
156 Grozinsky-Glasberg S, Alexandraki KI, Angelousi A, Chatzellis E, Sougioultzis S, Kaltsas G. Gastric Carcinoids. Endocrinol Metab Clin North Am. 2018;47:645-660. [PMID: 30098721 DOI: 10.1016/j.ecl.2018.04.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
157 Ortendahl JD, Pulgar SJ, Mirakhur B, Cox D, Bentley TG, Phan AT. Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals. Clinicoecon Outcomes Res 2017;9:495-503. [PMID: 28860831 DOI: 10.2147/CEOR.S140866] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
158 de Mestier L, Védie AL, Faron M, Cros J, Rebours V, Hentic O, Do Cao C, Bardet P, Lévy P, Sauvanet A, Ruszniewski P, Hammel P. The Postoperative Occurrence or Worsening of Diabetes Mellitus May Increase the Risk of Recurrence in Resected Pancreatic Neuroendocrine Tumors. Neuroendocrinology 2020;110:967-76. [PMID: 31791037 DOI: 10.1159/000505158] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
159 Cameselle-teijeiro JM, Mato Mato JA, Fernández Calvo O, García Mata J. Neuroendocrine Pulmonary Tumors of Low, Intermediate and High Grade: Anatomopathological Diagnosis—Prognostic and Predictive Factors. Mol Diagn Ther 2018;22:169-77. [DOI: 10.1007/s40291-018-0315-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
160 Iwata R, Maruyama M, Ito T, Nakano Y, Kanemura Y, Koike T, Oe S, Yoshimura K, Nonaka M, Nomura S, Sugimoto T, Yamada H, Asai A. Establishment of a tumor sphere cell line from a metastatic brain neuroendocrine tumor. Med Mol Morphol 2017;50:211-9. [PMID: 28516286 DOI: 10.1007/s00795-017-0160-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
161 Murtha TD, Lupsa BC, Majumdar S, Jain D, Salem RR. A Systematic Review of Proinsulin-Secreting Pancreatic Neuroendocrine Tumors. J Gastrointest Surg 2017;21:1335-41. [PMID: 28510792 DOI: 10.1007/s11605-017-3428-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
162 Sato K, Toyoshima Y, Moriyama S, Endo Y, Ito T, Ohki E. Real-world use of sunitinib in Japanese patients with pancreatic neuroendocrine tumors: results from a post-marketing surveillance study. Cancer Chemother Pharmacol 2019;83:201-7. [PMID: 30413868 DOI: 10.1007/s00280-018-3724-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
163 Colquhoun SD. Neuroendocrine tumors with hepatic metastases: A review of evolving treatment options. Liver Research 2018;2:92-9. [DOI: 10.1016/j.livres.2018.08.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
164 Ma Z, Cai H, Cui Y. Progress in the treatment of esophageal neuroendocrine carcinoma. Tumour Biol. 2017;39:1010428317711313. [PMID: 28653897 DOI: 10.1177/1010428317711313] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
165 Sharma N, Naraev BG, Engelman EG, Zimmerman MB, Bushnell DL Jr, OʼDorisio TM, OʼDorisio MS, Menda Y, Müller-Brand J, Howe JR, Halfdanarson TR. Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors. Pancreas 2017;46:151-6. [PMID: 27759712 DOI: 10.1097/MPA.0000000000000734] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 7.3] [Reference Citation Analysis]
166 McMullen T, Al-Jahdali A, de Gara C, Ghosh S, McEwan A, Schiller D. A population-based study of outcomes in patients with gastrointestinal neuroendocrine tumours. Can J Surg. 2017;60:192-197. [PMID: 28327275 DOI: 10.1503/cjs.007616] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
167 Rousseau E, Lau J, Zhang Z, Uribe CF, Kuo H, Zhang C, Zeisler J, Colpo N, Lin K, Bénard F. Effects of adding an albumin binder chain on [177Lu]Lu-DOTATATE. Nuclear Medicine and Biology 2018;66:10-7. [DOI: 10.1016/j.nucmedbio.2018.08.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
168 Kang J, Ryu JK, Son JH, Lee JW, Choi JH, Lee SH, Kim YT. Association between pathologic grade and multiphase computed tomography enhancement in pancreatic neuroendocrine neoplasm. J Gastroenterol Hepatol 2018. [PMID: 29514405 DOI: 10.1111/jgh.14139] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
169 Kinslow CJ, May MS, Saqi A, Shu CA, Chaudhary KR, Wang TJC, Cheng SK. Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study. Clin Lung Cancer 2020;21:e99-e113. [PMID: 31601526 DOI: 10.1016/j.cllc.2019.07.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
170 Jeremic MZ, Matovic MD, Krstic DZ, Pantovic SB, Nikezic DR. A five-compartment biokinetic model for 90 Y-DOTATOC therapy. Med Phys 2018;45:5577-85. [PMID: 30291717 DOI: 10.1002/mp.13229] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Rodriguez-Freixinos V, Thawer A, Capdevila J, Ferone D, Singh S. Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With? Curr Oncol Rep 2021;23:80. [PMID: 33937962 DOI: 10.1007/s11912-021-01071-5] [Reference Citation Analysis]
172 van Malderen K, Vijayvargiya P, Camilleri M, Larson DW, Cima R. Malignancy and Meckel's diverticulum: A systematic literature review and 14-year experience at a tertiary referral center. United European Gastroenterol J 2018;6:739-47. [PMID: 30083336 DOI: 10.1177/2050640617752771] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
173 Haq I, Krishna SG, Patel B, Thambi-Pillai T, Xie C, Odegaard K, Buohy K, Atiq M. The Impact of Repeating Endosonography with Confocal Endomicroscopy for the Diagnosis of Cystic Neuroendocrine Tumor. Case Rep Gastrointest Med 2019;2019:5187874. [PMID: 30755806 DOI: 10.1155/2019/5187874] [Reference Citation Analysis]
174 Cavalcoli F, Garrahy A, Castellaneta M, Tamagno G. Epidemiology of Neuroendocrine Tumours: By Site of Tumour and by Geographical Area. In: Colao A, Faggiano A, de Herder W, editors. Neuroendocrine Tumors in Real Life. Cham: Springer International Publishing; 2018. pp. 3-27. [DOI: 10.1007/978-3-319-59024-0_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
175 Adant S, Shah GM, Beauregard J. Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2020;47:907-21. [DOI: 10.1007/s00259-019-04499-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
176 Chin JL, O'Toole D. Diagnosis and Management of Upper Gastrointestinal Neuroendocrine Tumors. Clin Endosc. 2017;50:520-529. [PMID: 29207862 DOI: 10.5946/ce.2017.181] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
177 Starr JS, Sonbol MB, Hobday TJ, Sharma A, Kendi AT, Halfdanarson TR. Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights. Onco Targets Ther. 2020;13:3545-3555. [PMID: 32431509 DOI: 10.2147/ott.s202867] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
178 Shi M, Zhou B. Clinical Characteristics and Prognostic Factors of Early-Onset Pancreatic Neuroendocrine Tumors. Cancer Control 2021;28:1073274820986827. [PMID: 33491476 DOI: 10.1177/1073274820986827] [Reference Citation Analysis]
179 Gleeson FC, Voss JS, Kipp BR, Kerr SE, Van Arnam JS, Mills JR, Marcou CA, Schneider AR, Tu ZJ, Henry MR, Levy MJ. Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel. Oncotarget. 2017;8:93464-93475. [PMID: 29212165 DOI: 10.18632/oncotarget.18750] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
180 Rustgi SD, Oh A, Yang JY, Kang D, Wolin E, Kong CY, Hur C, Kim MK. Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis. BMC Cancer 2021;21:597. [PMID: 34030646 DOI: 10.1186/s12885-021-08306-5] [Reference Citation Analysis]
181 Brominska B, Gabryel P, Jarmołowska-Jurczyszyn D, Janicka-Jedyńska M, Kluk A, Trojanowski M, Brajer-Luftmann B, Woliński K, Czepczyński R, Gut P, Bromiński G, Majewski P, Dyszkiewicz W, Ruchała M. Klotho expression and nodal involvement as predictive factors for large cell lung carcinoma. Arch Med Sci 2019;15:1010-6. [PMID: 31360195 DOI: 10.5114/aoms.2018.75889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
182 Jiang R, Hong X, Zhao Y, Wu W. Application of multiomics sequencing and advances in the molecular mechanisms of pancreatic neuroendocrine neoplasms. Cancer Lett 2021;499:39-48. [PMID: 33246093 DOI: 10.1016/j.canlet.2020.11.012] [Reference Citation Analysis]
183 Perri G, Prakash LR, Katz MHG. Pancreatic neuroendocrine tumors. Curr Opin Gastroenterol 2019;35:468-77. [PMID: 31306159 DOI: 10.1097/MOG.0000000000000571] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
184 Sandini M, Strobel O, Hank T, Lewosinska M, Nießen A, Hackert T, Büchler MW, Schimmack S. Pre-operative dysglycemia is associated with decreased survival in patients with pancreatic neuroendocrine neoplasms. Surgery 2020;167:575-80. [PMID: 31889543 DOI: 10.1016/j.surg.2019.11.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
185 Horn SR, Stoltzfus KC, Lehrer EJ, Dawson LA, Tchelebi L, Gusani NJ, Sharma NK, Chen H, Trifiletti DM, Zaorsky NG. Epidemiology of liver metastases. Cancer Epidemiol 2020;67:101760. [PMID: 32562887 DOI: 10.1016/j.canep.2020.101760] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 14.0] [Reference Citation Analysis]
186 黄颖秋. 消化系统神经内分泌肿瘤的诊断和治疗现状. 世界华人消化杂志 2016; 24(17): 2625-2636 [DOI: 10.11569/wcjd.v24.i17.2625] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
187 Walter T, Planchard D, Bouledrak K, Scoazec J, Souquet P, Dussol A, Guigay J, Hervieu V, Berdelou A, Ducreux M, Arpin D, Lombard-bohas C, Baudin E. Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors. Lung Cancer 2016;96:68-73. [DOI: 10.1016/j.lungcan.2016.03.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
188 Leoncini E, Boffetta P, Shafir M, Aleksovska K, Boccia S, Rindi G. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine 2017;58:368-79. [PMID: 28303513 DOI: 10.1007/s12020-017-1273-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
189 Anafi RC, Francey LJ, Hogenesch JB, Kim J. CYCLOPS reveals human transcriptional rhythms in health and disease. Proc Natl Acad Sci U S A 2017;114:5312-7. [PMID: 28439010 DOI: 10.1073/pnas.1619320114] [Cited by in Crossref: 93] [Cited by in F6Publishing: 76] [Article Influence: 23.3] [Reference Citation Analysis]
190 Ren S, Qian L, Daniels MJ, Duan S, Chen R, Wang Z. Evaluation of contrast-enhanced computed tomography for the differential diagnosis of hypovascular pancreatic neuroendocrine tumors from chronic mass-forming pancreatitis. Eur J Radiol 2020;133:109360. [PMID: 33126171 DOI: 10.1016/j.ejrad.2020.109360] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
191 Masui T, Nagai K, Anazawa T, Kasai Y, Sato A, Nakano K, Uchida Y, Yogo A, Kawaguchi Y, Takaori K, Uemoto S. Risk factors for short recurrence-free survival after resection of pancreatic neuroendocrine tumor (PanNET) liver metastases: which patients should undergo resection? Scand J Gastroenterol 2020;55:479-84. [PMID: 32223573 DOI: 10.1080/00365521.2020.1743352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
192 Leoncini E, Carioli G, La Vecchia C, Boccia S, Rindi G. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. Ann Oncol 2016;27:68-81. [PMID: 26487581 DOI: 10.1093/annonc/mdv505] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
193 Lee L, Igarashi H, Fujimori N, Hijioka M, Kawabe K, Oda Y, Jensen RT, Ito T. Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study. Jpn J Clin Oncol 2015;45:1131-8. [PMID: 26378090 DOI: 10.1093/jjco/hyv143] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
194 Imperatore N, de Nucci G, Mandelli ED, de Leone A, Zito FP, Lombardi G, Manes G. Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: a systematic review of the literature. Endosc Int Open 2020;8:E1759-64. [PMID: 33269308 DOI: 10.1055/a-1261-9605] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
195 Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, Lawlor R, Marinoni I, Perren A, Scarpa A, Sorbye H, Pavel ME, Weber MM, Modlin I, Gress TM. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Gut 2021;70:1768-81. [PMID: 33692095 DOI: 10.1136/gutjnl-2020-321300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
196 Carmona-Bayonas A, Jiménez-Fonseca P, Custodio A, Grande E, Capdevila J, López C, Teule A, Garcia-Carbonero R; Spanish Neuroendocrine Tumor Group (GETNE). Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Curr Oncol Rep 2017;19:72. [PMID: 28920153 DOI: 10.1007/s11912-017-0633-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
197 De Rycke O, Védie AL, Guarneri G, Nin F, De Flori C, Hentic O, Idri S, Sauvanet A, Rebours V, Cros J, Couvelard A, Ruszniewski P, de Mestier L. O-positive blood type is associated with prolonged recurrence-free survival following curative resection of pancreatic neuroendocrine tumors. Pancreatology 2020;20:1718-22. [PMID: 33032924 DOI: 10.1016/j.pan.2020.09.014] [Reference Citation Analysis]
198 Hallet J, Law CHL, Cheung M, Mittmann N, Liu N, Fischer HD, Singh S. Patterns and Drivers of Costs for Neuroendocrine Tumor Care: A Comparative Population-Based Analysis. Ann Surg Oncol 2017;24:3312-23. [DOI: 10.1245/s10434-017-5986-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
199 Vitali E, Boemi I, Tarantola G, Piccini S, Zerbi A, Veronesi G, Baldelli R, Mazziotti G, Smiroldo V, Lavezzi E, Spada A, Mantovani G, Lania AG. Metformin and Everolimus: A Promising Combination for Neuroendocrine Tumors Treatment. Cancers (Basel). 2020;12. [PMID: 32748870 DOI: 10.3390/cancers12082143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
200 Cavalcanti MS, Gönen M, Klimstra DS. The ENETS/WHO grading system for neuroendocrine neoplasms of the gastroenteropancreatic system: a review of the current state, limitations and proposals for modifications. Int J Endocr Oncol 2016;3:203-19. [PMID: 30338051 DOI: 10.2217/ije-2016-0006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
201 Yao JC, Oh DY, Qian J, Park YS, Herbst F, Ridolfi A, Izquierdo M, Ito T, Jia L, Komoto I, Sriuranpong V, Shimada Y. Everolimus for the treatment of advanced gastrointestinal or lung nonfunctional neuroendocrine tumors in East Asian patients: a subgroup analysis of the RADIANT-4 study. Onco Targets Ther 2019;12:1717-28. [PMID: 30881026 DOI: 10.2147/OTT.S182259] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
202 Lamberti G, Brighi N, Maggio I, Manuzzi L, Peterle C, Ambrosini V, Ricci C, Casadei R, Campana D. The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy? Int J Mol Sci. 2018;19. [PMID: 29509701 DOI: 10.3390/ijms19030747] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
203 Barrio M, Ceppa EP. Diagnosing microscopic pancreatic neuroendocrine tumor using 68-Ga-DOTATATE PET/CT: case series. J Surg Case Rep. 2018;2018:rjy237. [PMID: 30283629 DOI: 10.1093/jscr/rjy237] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
204 Singh S, Sivajohanathan D, Asmis T, Cho C, Hammad N, Law C, Wong R, Zbuk K. Systemic therapy in incurable gastroenteropancreatic neuroendocrine tumours: a clinical practice guideline. Curr Oncol 2017;24:249-55. [PMID: 28874893 DOI: 10.3747/co.24.3634] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
205 Gao L, Natov NS, Daly KP, Masud F, Chaudhry S, Sterling MJ, Saif MW. An update on the management of pancreatic neuroendocrine tumors. Anticancer Drugs. 2018;29:597-612. [PMID: 29782352 DOI: 10.1097/cad.0000000000000633] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
206 Zhu X, Pigazzi A, Zell J, Lu Y. Changing Disparity of Gastric Cancer Incidence by Histological Types in US Race-Specific Populations. Cancer Control 2020;27:1073274820977152. [PMID: 33297759 DOI: 10.1177/1073274820977152] [Reference Citation Analysis]
207 de Mestier L, Lepage C, Baudin E, Coriat R, Courbon F, Couvelard A, Do Cao C, Frampas E, Gaujoux S, Gincul R, Goudet P, Lombard-Bohas C, Poncet G, Smith D, Ruszniewski P, Lecomte T, Bouché O, Walter T, Cadiot G; Thésaurus National de Cancérologie Digestive (TNCD). Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis 2020;52:473-92. [PMID: 32234416 DOI: 10.1016/j.dld.2020.02.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 21.0] [Reference Citation Analysis]
208 Berends AMA, Buitenwerf E, de Krijger RR, Veeger NJGM, van der Horst-Schrivers ANA, Links TP, Kerstens MN. Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: A nationwide study and systematic review. Eur J Intern Med. 2018;51:68-73. [PMID: 29361475 DOI: 10.1016/j.ejim.2018.01.015] [Cited by in Crossref: 77] [Cited by in F6Publishing: 60] [Article Influence: 25.7] [Reference Citation Analysis]
209 Yang M, Zhang Y, Zeng L, Ke NW, Tan CL, Tian BL, Xiang B, Liu XB. Survivals of patients with surgically treated and High-grade pancreatic neuroendocrine carcinomas: A comparative study between two American Joint Committee on Cancer 8th tumor-node-metastasis staging systems. Eur J Surg Oncol 2019;45:1054-60. [PMID: 30661921 DOI: 10.1016/j.ejso.2019.01.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
210 Boca S, Farcau C, Baia M, Astilean S. Metanephrine neuroendocrine tumor marker detection by SERS using Au nanoparticle/Au film sandwich architecture. Biomed Microdevices 2016;18. [DOI: 10.1007/s10544-016-0037-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
211 Zellmer J, Yen HY, Kaiser L, Mille E, Gildehaus FJ, Böning G, Steiger K, Hacker M, Bartenstein P, Todica A, Haug AR, Ilhan H. Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu]Lu-DOTA-TATE in Lewis rats. EJNMMI Res 2020;10:41. [PMID: 32335736 DOI: 10.1186/s13550-020-00628-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
212 Yang M, Zeng L, Yao WQ, Ke NW, Tan CL, Tian BL, Liu XB, Xiang B, Zhang Y. A comprehensive validation of the novel 8th edition of American Joint Committee on Cancer staging manual for the long-term survivals of patients with non-functional pancreatic neuroendocrine neoplasms. Medicine (Baltimore) 2020;99:e22291. [PMID: 33181635 DOI: 10.1097/MD.0000000000022291] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
213 Tafuto S, von Arx C, Capozzi M, Tatangelo F, Mura M, Modica R, Barretta ML, Di Sarno A, Tornesello ML, Colao A, Ottaiano A. Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms. J Clin Med 2019;8:E1224. [PMID: 31443197 DOI: 10.3390/jcm8081224] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
214 Broder MS, Cai B, Chang E, Neary MP. Epidemiology of Gastrointestinal Neuroendocrine Tumors in a U.S. Commercially Insured Population. Endocrine Practice 2017;23:1210-6. [DOI: 10.4158/ep171879.or] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
215 Pusceddu S, Prinzi N, Lo Russo G, Femia D, Milione M, Perrone F, Tamborini E, Concas L, Pulice I, Vernieri C, Corti F, Buzzoni R, de Braud F. Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors. Future Oncol 2017;13:1677-83. [PMID: 28580793 DOI: 10.2217/fon-2017-0132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
216 Liu IH, Kunz PL. Biologics in gastrointestinal and pancreatic neuroendocrine tumors. J Gastrointest Oncol 2017;8:457-65. [PMID: 28736633 DOI: 10.21037/jgo.2016.12.09] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
217 Liu Q, Zang J, Sui H, Ren J, Guo H, Wang H, Wang R, Jacobson O, Zhang J, Cheng Y, Zhu Z, Chen X. Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of 177Lu-DOTA-EB-TATE. J Nucl Med 2021;62:386-92. [PMID: 32826319 DOI: 10.2967/jnumed.120.248658] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
218 Cavalcoli F, Pusceddu S, Zilli A, Tamagno G, Femia D, Prinzi N, Travers J, Consonni D, Ciafardini C, Conte D, Massironi S. Effects of low-dose aspirin on clinical outcome and disease progression in patients with gastroenteropancreatic neuroendocrine neoplasm. Scand J Gastroenterol 2019;54:1111-7. [PMID: 31454281 DOI: 10.1080/00365521.2019.1656773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
219 Boyar Cetinkaya R, Aagnes B, Myklebust TÅ, Thiis-Evensen E. Survival in neuroendocrine neoplasms; A report from a large Norwegian population-based study. Int J Cancer 2018;142:1139-47. [PMID: 29082524 DOI: 10.1002/ijc.31137] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
220 Sohail S, Zuk V, Halfdanarson T, Chan D, Pattison S, Vasdev R, Law C, Hallet J. The Quality of Online Information for an Uncommon Malignancy-Neuroendocrine Tumours (NETs). Curr Oncol 2021;28:842-6. [PMID: 33567619 DOI: 10.3390/curroncol28010082] [Reference Citation Analysis]
221 Fujii Y, Kobayashi K, Kimura S, Uehara S, Miyai H, Takiguchi S. Indications for lateral lymph node dissection in patients with rectal neuroendocrine tumors: A case report and review of the literature. Mol Clin Oncol 2021;14:80. [PMID: 33758661 DOI: 10.3892/mco.2021.2242] [Reference Citation Analysis]
222 Hasic Telalovic J, Pillozzi S, Fabbri R, Laffi A, Lavacchi D, Rossi V, Dreoni L, Spada F, Fazio N, Amedei A, Iadanza E, Antonuzzo L. A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy. Diagnostics (Basel) 2021;11:804. [PMID: 33925256 DOI: 10.3390/diagnostics11050804] [Reference Citation Analysis]
223 Tsang ES, McConnell YJ, Schaeffer DF, Lee L, Yin Y, Zerhouni S, Schaff K, Speers C, Kennecke HF. Outcomes of Surgical and Chemotherapeutic Treatments of Goblet Cell Carcinoid Tumors of the Appendix. Ann Surg Oncol 2018;25:2391-9. [PMID: 29916007 DOI: 10.1245/s10434-018-6560-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
224 Twito O, Paran H, Avital S, Kravtsov V, Rosenblum RC, Rotman-Pikielny P, Klein N. Temporal trends in incidence, evaluation and management of neuroendocrine neoplasms of the appendix: 14 years' experience. Am J Surg 2021;221:1000-4. [PMID: 33004142 DOI: 10.1016/j.amjsurg.2020.09.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
225 Chakedis J, Beal EW, Lopez-aguiar AG, Poultsides G, Makris E, Rocha FG, Kanji Z, Weber S, Fisher A, Fields R, Krasnick BA, Idrees K, Marincola-smith P, Cho C, Beems M, Pawlik TM, Maithel SK, Schmidt CR, Dillhoff M. Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms. J Gastrointest Surg 2019;23:122-34. [DOI: 10.1007/s11605-018-3986-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
226 Cunha Júnior AD, Bragagnoli AC, Costa FO, Carvalheira JBC. Repurposing metformin for the treatment of gastrointestinal cancer. World J Gastroenterol 2021; 27(17): 1883-1904 [PMID: 34007128 DOI: 10.3748/wjg.v27.i17.1883] [Reference Citation Analysis]
227 Asban A, Patel AJ, Reddy S, Wang T, Balentine CJ, Chen H. Cancer of the Endocrine System. Abeloff's Clinical Oncology. Elsevier; 2020. pp. 1074-1107.e11. [DOI: 10.1016/b978-0-323-47674-4.00068-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Mujica-Mota R, Varley-Campbell J, Tikhonova I, Cooper C, Griffin E, Haasova M, Peters J, Lucherini S, Talens-Bou J, Long L, Sherriff D, Napier M, Ramage J, Hoyle M. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. Health Technol Assess 2018;22:1-326. [PMID: 30209002 DOI: 10.3310/hta22490] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
229 Sobotka LA, Hake T, Kelly C, Mousa L. Metastatic neuroendocrine carcinoma presenting as multifocal liver lesions with elevated alpha-fetoprotein. Clin Case Rep. 2019;7:251-253. [PMID: 30847183 DOI: 10.1002/ccr3.1956] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
230 Andreasi V, Partelli S, Muffatti F, Manzoni MF, Capurso G, Falconi M. Update on gastroenteropancreatic neuroendocrine tumors. Dig Liver Dis. 2021;53:171-182. [PMID: 32912771 DOI: 10.1016/j.dld.2020.08.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 de Nucci G, Imperatore N, Mandelli ED, di Nuovo F, d'Urbano C, Manes G. Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: a case series. Endosc Int Open 2020;8:E1754-8. [PMID: 33269307 DOI: 10.1055/a-1261-9359] [Reference Citation Analysis]
232 Leyden J, Pavlakis N, Chan D, Michael M, Clarke S, Khasraw M, Price T. Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey. Asia-Pac J Clin Oncol 2018;14:256-63. [DOI: 10.1111/ajco.12785] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
233 Tirosh A, Kebebew E. Genetic and epigenetic alterations in pancreatic neuroendocrine tumors. J Gastrointest Oncol 2020;11:567-77. [PMID: 32655936 DOI: 10.21037/jgo.2020.03.11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
234 Luque RM, Sampedro-Nuñez M, Gahete MD, Ramos-Levi A, Ibáñez-Costa A, Rivero-Cortés E, Serrano-Somavilla A, Adrados M, Culler MD, Castaño JP, Marazuela M. In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution and aggressiveness of human neuroendocrine tumors: Evidence from clinical, cellular and molecular parameters. Oncotarget 2015;6:19619-33. [PMID: 26124083 DOI: 10.18632/oncotarget.4316] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
235 Jaqua E, Nguyen V, Pan V, Cereser C. A Common Concern With a Rare Diagnosis: Pancreatic Neuroendocrine Neoplasms. Cureus 2021;13:e17767. [PMID: 34659978 DOI: 10.7759/cureus.17767] [Reference Citation Analysis]
236 Andre A, Squittieri N, Patil SB. Evaluation of the Octreotide Acetate Pen Injector and its Instructions for Use in a Formative Human Factors Study. Adv Ther 2021;38:3129-42. [PMID: 33948925 DOI: 10.1007/s12325-021-01739-1] [Reference Citation Analysis]
237 Broecker JS, Ethun CG, Postlewait LM, Le N, Mcinnis M, Russell MC, Sullivan P, Kooby DA, Staley CA, Maithel SK, Cardona K. Colon and Rectal Neuroendocrine Tumors: Are They Really One Disease? A Single-Institution Experience over 15 Years. The American Surgeon 2018;84:717-26. [DOI: 10.1177/000313481808400525] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
238 Calin ML, Sadiq A, Arevalo G, Fuentes R, Flanders VL, Gupta N, Nasri B, Singh K. The First Case Report of Robotic Multivisceral Resection for Synchronous Liver Metastasis from Pancreatic Neuroendocrine Tumor: A Case Report and Literature Review. J Laparoendosc Adv Surg Tech A 2016;26:816-24. [PMID: 27454160 DOI: 10.1089/lap.2016.0342] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
239 Carter CA, Schmitz B, Peterson PG, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid TR, Cabrales P, Brzezniak C. Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. Case Rep Oncol 2016;9:164-70. [PMID: 27065848 DOI: 10.1159/000444633] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
240 Rossi RE, Ciafardini C, Sciola V, Conte D, Massironi S. Chromogranin A in the Follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms: Is It Really Game Over? A Systematic Review and Meta-analysis. Pancreas 2018;47:1249-55. [PMID: 30325865 DOI: 10.1097/MPA.0000000000001184] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
241 Scott AT, Breheny PJ, Keck KJ, Bellizzi AM, Dillon JS, O'Dorisio TM, Howe JR. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs). Surgery. 2019;165:166-175. [PMID: 30343949 DOI: 10.1016/j.surg.2018.04.070] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
242 Isenberg-Grzeda E, MacGregor M, Matsoukas K, Chow N, Reidy-Lagunes D, Alici Y. Must antidepressants be avoided in patients with neuroendocrine tumors? Results of a systematic review. Palliat Support Care 2020;18:602-8. [PMID: 32036806 DOI: 10.1017/S147895152000005X] [Reference Citation Analysis]
243 Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, Cremonesi M, de Herder WW, Dromain C, Falconi M, Fani M, Fanti S, Hicks RJ, Kabasakal L, Kaltsas G, Lewington V, Minozzi S, Cinquini M, Öberg K, Oyen WJG, O'Toole D, Pavel M, Ruszniewski P, Scarpa A, Strosberg J, Sundin A, Taïeb D, Virgolini I, Wild D, Herrmann K, Yao J. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer 2021;146:56-73. [PMID: 33588146 DOI: 10.1016/j.ejca.2021.01.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
244 Yang M, Zhang Y, Zeng L, Ke NW, Tan CL, Tian BL, Xiang B, Liu XB. Prognostic Validity of the American Joint Committee on Cancer Eighth Edition TNM Staging System for Surgically Treated and Well-Differentiated Pancreatic Neuroendocrine Tumors: A Comprehensive Analysis of 254 Consecutive Patients From a Large Chinese Institution. Pancreas. 2019;48:613-621. [PMID: 31091206 DOI: 10.1097/mpa.0000000000001305] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 11.0] [Reference Citation Analysis]
245 Singh S, Granberg D, Wolin E, Warner R, Sissons M, Kolarova T, Goldstein G, Pavel M, Öberg K, Leyden J. Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs. J Glob Oncol 2017;3:43-53. [PMID: 28717741 DOI: 10.1200/JGO.2015.002980] [Cited by in Crossref: 46] [Cited by in F6Publishing: 32] [Article Influence: 9.2] [Reference Citation Analysis]
246 Baretti M, Zhu Q, Zahurak M, Bhaijee F, Xu H, Engle EL, Kotte A, Pawlik TM, Anders RA, De Jesus-Acosta A. Prognostic Implications of the Immune Tumor Microenvironment in Patients With Pancreatic and Gastrointestinal Neuroendocrine Tumors. Pancreas 2021;50:719-26. [PMID: 34016898 DOI: 10.1097/MPA.0000000000001831] [Reference Citation Analysis]
247 Hallet J, Davis LE, Mahar AL, Law CHL, Isenberg-Grzeda E, Bubis LD, Singh S, Myrehaug S, Zhao H, Beyfuss K, Moody L, Coburn NG. Patterns of Symptoms Burden in Neuroendocrine Tumors: A Population-Based Analysis of Prospective Patient-Reported Outcomes. Oncologist 2019;24:1384-94. [PMID: 31270268 DOI: 10.1634/theoncologist.2019-0112] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
248 Lal P, Saleh MA, Khoudari G, Gad MM, Mansoor E, Isenberg G, Cooper GS. Epidemiology of Large Bowel Carcinoid Tumors in the USA: A Population-Based National Study. Dig Dis Sci 2020;65:269-75. [DOI: 10.1007/s10620-019-05725-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
249 Lim LE, Chan DL, Thomas D, Du Y, Tincknell G, Kuchel A, Davis A, Bailey DL, Pavlakis N, Cehic G, Macdonald W, Wyld D, Segelov E. Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours. Oncotarget 2020;11:2636-46. [PMID: 32676165 DOI: 10.18632/oncotarget.27659] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
250 Begum N, Maasberg S, Pascher A, Plöckinger U, Gress TM, Wurst C, Weber F, Raffel A, Krausch M, Holzer K, Bartsch DK, Musholt TJ, Keck T, Anlauf M, Rinke A, Pape UF, Goretzki PE; German NET-Registry. Long-term outcome of surgical resection in patients with gastroenteropancreatic neuroendocrine neoplasia: results from a German nation-wide multi-centric registry. Langenbecks Arch Surg 2020;405:145-54. [PMID: 32372309 DOI: 10.1007/s00423-020-01868-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
251 Vitali E, Piccini S, Trivellin G, Smiroldo V, Lavezzi E, Zerbi A, Pepe G, Lania AG. The impact of SST2 trafficking and signaling in the treatment of pancreatic neuroendocrine tumors. Mol Cell Endocrinol 2021;527:111226. [PMID: 33675866 DOI: 10.1016/j.mce.2021.111226] [Reference Citation Analysis]
252 Wetz C, Rogasch J, Genseke P, Schatka I, Furth C, Kreissl M, Jann H, Venerito M, Amthauer H. Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment? Diagnostics (Basel) 2020;10:E732. [PMID: 32971877 DOI: 10.3390/diagnostics10090732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
253 Scott AT, Pelletier D, Maxwell JE, Sherman SK, Keck KJ, Li G, Dillon JS, O'Dorisio TM, Bellizzi AM, Howe JR. The Pancreas as a Site of Metastasis or Second Primary in Patients with Small Bowel Neuroendocrine Tumors. Ann Surg Oncol 2019;26:2525-32. [PMID: 31011904 DOI: 10.1245/s10434-019-07370-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
254 Cataldi C, Cerasari S, Poillucci G, Capaldi M, Scocchera F, Trombetta S, Fransvea P, Mazzarella-Farao R, Marini P. Metastatic retroperitoneal tumor from a non-functional neuroendocrine neoplasia of the left ethmoid-nose-orbitary region: Case report and short review of literature. Int J Surg Case Rep 2020;66:169-73. [PMID: 31862660 DOI: 10.1016/j.ijscr.2019.12.001] [Reference Citation Analysis]
255 Kjaer J, Stålberg P, Crona J, Welin S, Hellman P, Thornell A, Norlen O. Long-term outcome after resection and thermal hepatic ablation of pancreatic neuroendocrine tumour liver metastases. BJS Open 2021;5:zrab062. [PMID: 34291287 DOI: 10.1093/bjsopen/zrab062] [Reference Citation Analysis]
256 Kalshetty A, Ramaswamy A, Ostwal V, Basu S. Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting. Nuclear Medicine Communications 2018;39:1143-9. [DOI: 10.1097/mnm.0000000000000926] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
257 Sibeoni J, Khannoussi W, Manolios E, Rebours V, Revah-Levy A, Ruszniewski P. Perspectives of patients and physicians about neuroendocrine tumors. A qualitative study. Oncotarget 2018;9:14138-47. [PMID: 29581833 DOI: 10.18632/oncotarget.24347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
258 Oleinikov K, Dancour A, Epshtein J, Benson A, Mazeh H, Tal I, Matalon S, Benbassat CA, Livovsky DM, Goldin E, Gross DJ, Jacob H, Grozinsky-Glasberg S. Endoscopic Ultrasound-Guided Radiofrequency Ablation: A New Therapeutic Approach for Pancreatic Neuroendocrine Tumors. J Clin Endocrinol Metab 2019;104:2637-47. [PMID: 31102458 DOI: 10.1210/jc.2019-00282] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 22.0] [Reference Citation Analysis]
259 Chua A, Perrin A, Ricci JF, Neary MP, Thabane M. Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada. Curr Oncol 2018;25:32-40. [PMID: 29507481 DOI: 10.3747/co.25.3532] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
260 Peltola E, Hannula P, Huhtala H, Metso S, Kiviniemi U, Vornanen M, Sand J, Laukkarinen J, Tiikkainen M, Schalin-Jäntti C, Arola J, Sirén J, Piiroinen A, Soinio M, Nuutila P, Söderström M, Hämäläinen H, Moilanen L, Laaksonen D, Pirinen E, Sundelin F, Ebeling T, Salmela P, Mäkinen MJ, Jaatinen P. Characteristics and Outcomes of 79 Patients with an Insulinoma: A Nationwide Retrospective Study in Finland. Int J Endocrinol 2018;2018:2059481. [PMID: 30425741 DOI: 10.1155/2018/2059481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
261 DePalo DK, Lee RM, Lopez-Aguiar AG, Gamboa AC, Rocha F, Poultsides G, Dillhoff M, Fields RC, Idrees K, Nathan H, Abbott D, Maithel SK, Russell MC; other members of the United States Neuroendocrine Tumor Study Group. Interaction of race and pathology for neuroendocrine tumors: Epidemiology, natural history, or racial disparity? J Surg Oncol 2019;120:919-25. [PMID: 31385621 DOI: 10.1002/jso.25662] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
262 Deng BY, Yang M, Wen JY, Hou SZ, Chen Y, Tian BL, Liu XB, Zhang Y. Survivals of patients with pancreatic neuroendocrine carcinomas: An in-depth analysis by the American Joint Committee on Cancer 8th tumor-node-metastasis staging manual. Medicine (Baltimore) 2020;99:e18736. [PMID: 32011453 DOI: 10.1097/MD.0000000000018736] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
263 Hauck L, Bitzer M, Malek N, Plentz RR. Subgroup analysis of patients with G2 gastroenteropancreatic neuroendocrine tumors. Scand J Gastroenterol. 2016;51:55-59. [PMID: 26137871 DOI: 10.3109/00365521.2015.1064994] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
264 Soyano AE, Kassi M, Kasi PM. Neuroendocrine Tumor Involving the Epicardium. Case Rep Oncol 2017;10:1144-9. [PMID: 29430241 DOI: 10.1159/000485560] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
265 Fairweather M, Swanson R, Wang J, Brais LK, Dutton T, Kulke MH, Clancy TE. Management of Neuroendocrine Tumor Liver Metastases: Long-Term Outcomes and Prognostic Factors from a Large Prospective Database. Ann Surg Oncol. 2017;24:2319-2325. [PMID: 28303430 DOI: 10.1245/s10434-017-5839-x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 12.3] [Reference Citation Analysis]
266 Neychev V, Kebebew E. Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature. Int J Surg Oncol 2017;2017:6424812. [PMID: 28593056 DOI: 10.1155/2017/6424812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
267 Li G, Tian ML, Bing YT, Wang HY, Yuan CH, Xiu DR. Nomograms predict survival outcomes for distant metastatic pancreatic neuroendocrine tumor: A population based STROBE compliant study. Medicine (Baltimore) 2020;99:e19593. [PMID: 32221079 DOI: 10.1097/MD.0000000000019593] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
268 Singh S, Poon R, Wong R, Metser U. 68Ga PET Imaging in Patients With Neuroendocrine Tumors: A Systematic Review and Meta-analysis. Clin Nucl Med 2018;43:802-10. [DOI: 10.1097/rlu.0000000000002276] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
269 Zhang J, Song Q, Cai L, Xie Y, Chen Y. The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2020;146:1533-43. [PMID: 32281025 DOI: 10.1007/s00432-020-03181-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
270 Hall NC, Bluemel C, Vidal-sicart S, Povoski SP. Radioguided Surgery for Gastroenteropancreatic Neuroendocrine Tumors. In: Herrmann K, Nieweg OE, Povoski SP, editors. Radioguided Surgery. Cham: Springer International Publishing; 2016. pp. 299-311. [DOI: 10.1007/978-3-319-26051-8_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
271 Watanabe A, Yip L, Hamilton TD, Loree JM, Stuart HC. Tumour grade and primary site predict patterns of recurrence and survival in patients with resected gastroenteropancreatic neuroendocrine tumors. Am J Surg 2021;221:1141-9. [PMID: 33795127 DOI: 10.1016/j.amjsurg.2021.03.027] [Reference Citation Analysis]
272 Tierney JF, Chivukula SV, Wang X, Pappas SG, Schadde E, Hertl M, Poirier J, Keutgen XM. Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors. Surgery 2019;165:644-51. [DOI: 10.1016/j.surg.2018.09.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 13.5] [Reference Citation Analysis]
273 Mirallas O, Saoudi N, Gómez-Puerto D, Riveiro-Barciela M, Merino X, Auger C, Landolfi S, Blanco L, Garcia-Burillo A, Molero X, Salcedo-Allende MT, Capdevila J. Acquired hepatocerebral degeneration in a metastatic neuroendocrine tumor long-term survivor — an update on neuroendocrine neoplasm’s treatment: A case report. World J Hepatol 2021; 13(5): 611-619 [PMID: 34131474 DOI: 10.4254/wjh.v13.i5.611] [Reference Citation Analysis]
274 Wu L, Fu J, Wan L, Pan J, Lai S, Zhong J, Chung DC, Wang L. Survival outcomes and surgical intervention of small intestinal neuroendocrine tumors: a population based retrospective study. Oncotarget. 2017;8:4935-4947. [PMID: 27903960 DOI: 10.18632/oncotarget.13632] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
275 Jiang M, Tan Y, Li X, Fu J, Hu H, Ye X, Cao Y, Xu J, Yuan Y. Clinicopathological Features and Prognostic Factors of Colorectal Neuroendocrine Neoplasms. Gastroenterol Res Pract 2017;2017:4206172. [PMID: 28194176 DOI: 10.1155/2017/4206172] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
276 Lindström M, Tohmola N, Renkonen R, Hämäläinen E, Schalin-Jäntti C, Itkonen O. Comparison of serum serotonin and serum 5-HIAA LC-MS/MS assays in the diagnosis of serotonin producing neuroendocrine neoplasms: A pilot study. Clin Chim Acta 2018;482:78-83. [PMID: 29596816 DOI: 10.1016/j.cca.2018.03.030] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
277 Zhang R, Zhu Y, Huang XB, Deng C, Li M, Shen GS, Huang SL, Huangfu SH, Liu YN, Zhou CG, Wang L, Zhang Q, Deng Y, Jiang B. Primary neuroendocrine tumor in the presacral region: A case report. World J Clin Cases 2019; 7(14): 1884-1891 [PMID: 31417935 DOI: 10.12998/wjcc.v7.i14.1884] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
278 Pusceddu S, Vernieri C, Di Maio M, Marconcini R, Spada F, Massironi S, Ibrahim T, Brizzi MP, Campana D, Faggiano A, Giuffrida D, Rinzivillo M, Cingarlini S, Aroldi F, Antonuzzo L, Berardi R, Catena L, De Divitiis C, Ermacora P, Perfetti V, Fontana A, Razzore P, Carnaghi C, Davì MV, Cauchi C, Duro M, Ricci S, Fazio N, Cavalcoli F, Bongiovanni A, La Salvia A, Brighi N, Colao A, Puliafito I, Panzuto F, Ortolani S, Zaniboni A, Di Costanzo F, Torniai M, Bajetta E, Tafuto S, Garattini SK, Femia D, Prinzi N, Concas L, Lo Russo G, Milione M, Giacomelli L, Buzzoni R, Delle Fave G, Mazzaferro V, de Braud F. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. Gastroenterology 2018;155:479-489.e7. [PMID: 29655834 DOI: 10.1053/j.gastro.2018.04.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
279 Sackstein PE, O'Neil DS, Neugut AI, Chabot J, Fojo T. Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years. Semin Oncol 2018;45:249-58. [PMID: 30348533 DOI: 10.1053/j.seminoncol.2018.07.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
280 Chauhan A, Yu Q, Ray N, Farooqui Z, Huang B, Durbin EB, Tucker T, Evers M, Arnold S, Anthony LB. Global burden of neuroendocrine tumors and changing incidence in Kentucky. Oncotarget 2018;9:19245-54. [PMID: 29721198 DOI: 10.18632/oncotarget.24983] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
281 Singh S, Asa SL, Dey C, Kennecke H, Laidley D, Law C, Asmis T, Chan D, Ezzat S, Goodwin R. Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus. Cancer Treat Rev. 2016;47:32-45. [PMID: 27236421 DOI: 10.1016/j.ctrv.2016.05.003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
282 Cui Y, Li ZW, Li XT, Gao SY, Li Y, Li J, Zhu HC, Tang L, Cao K, Sun YS. Dynamic enhanced CT: is there a difference between liver metastases of gastroenteropancreatic neuroendocrine tumor and adenocarcinoma. Oncotarget 2017;8:108146-55. [PMID: 29296230 DOI: 10.18632/oncotarget.22554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
283 Sitani K, Parghane RV, Talole S, Basu S. Long-term outcome of indigenous 177Lu-DOTATATE PRRT in patients with Metastatic Advanced Neuroendocrine Tumours: a single institutional observation in a large tertiary care setting. Br J Radiol 2021;94:20201041. [PMID: 33095671 DOI: 10.1259/bjr.20201041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
284 Chan D, Moody L, Segelov E, Metz D, Strosberg J, Pavlakis N, Singh S. Follow-Up for Resected Gastroenteropancreatic Neuroendocrine Tumours: A Practice Survey of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) and the North American Neuroendocrine Tumor Society (NANETS). Neuroendocrinology 2018;107:32-41. [DOI: 10.1159/000488394] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
285 Pusceddu S, Buzzoni R, Vernieri C, Concas L, Marceglia S, Giacomelli L, Milione M, Leuzzi L, Femia D, Formisano B, Mazzaferro V, de Braud F. Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. Future Oncol 2016;12:1251-60. [PMID: 26890290 DOI: 10.2217/fon-2015-0077] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
286 Yang M, Zeng L, Ke NW, Tan CL, Tian BL, Liu XB, Xiang B, Zhang Y. Validation of the Novel Eighth Edition of American Joint Committee on Cancer Staging Manual: An In-depth Analysis for Nonfunctional Pancreatic Neuroendocrine Neoplasms. Pancreas 2020;49:e42-3. [PMID: 32433414 DOI: 10.1097/MPA.0000000000001553] [Reference Citation Analysis]
287 Moeckli B, Ivanics T, Claasen M, Toso C, Sapisochin G. Recent developments and ongoing trials in transplant oncology. Liver Int 2020;40:2326-44. [PMID: 33021344 DOI: 10.1111/liv.14621] [Reference Citation Analysis]
288 Merath K, Bagante F, Beal EW, Lopez-Aguiar AG, Poultsides G, Makris E, Rocha F, Kanji Z, Weber S, Fisher A, Fields R, Krasnick BA, Idrees K, Smith PM, Cho C, Beems M, Schmidt CR, Dillhoff M, Maithel SK, Pawlik TM. Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group. J Surg Oncol. 2018;117:868-878. [PMID: 29448303 DOI: 10.1002/jso.24985] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
289 Chan DL, Clarke SJ, Diakos CI, Roach PJ, Bailey DL, Singh S, Pavlakis N. Prognostic and predictive biomarkers in neuroendocrine tumours. Critical Reviews in Oncology/Hematology 2017;113:268-82. [DOI: 10.1016/j.critrevonc.2017.03.017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
290 Vesterinen T, Salmenkivi K, Mustonen H, Kuopio T, Lappi-Blanco E, Paavonen T, Vainio P, Knuuttila A, Carpén O, Haglund C, Arola J. Performance of Finnish biobanks in nationwide pulmonary carcinoid tumour research. Virchows Arch 2020;476:273-83. [PMID: 31385069 DOI: 10.1007/s00428-019-02625-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
291 Bodei L, Kidd M, Modlin IM, Prasad V, Severi S, Ambrosini V, Kwekkeboom DJ, Krenning EP, Baum RP, Paganelli G, Drozdov I. Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status. Eur J Nucl Med Mol Imaging 2015;42:1341-52. [DOI: 10.1007/s00259-015-3075-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
292 Altieri B, Barrea L, Modica R, Muscogiuri G, Savastano S, Colao A, Faggiano A. Nutrition and neuroendocrine tumors: An update of the literature. Rev Endocr Metab Disord 2018;19:159-67. [PMID: 30267297 DOI: 10.1007/s11154-018-9466-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
293 Vitali E, Boemi I, Piccini S, Tarantola G, Smiroldo V, Lavezzi E, Brambilla T, Zerbi A, Carnaghi C, Mantovani G, Spada A, Lania AG. A novel insight into the anticancer mechanism of metformin in pancreatic neuroendocrine tumor cells. Mol Cell Endocrinol 2020;509:110803. [PMID: 32251713 DOI: 10.1016/j.mce.2020.110803] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
294 Cao LL, Lu J, Lin JX, Zheng CH, Li P, Xie JW, Wang JB, Chen QY, Lin M, Tu RH, Huang CM. Incidence and survival trends for gastric neuroendocrine neoplasms: An analysis of 3523 patients in the SEER database. Eur J Surg Oncol. 2018;44:1628-1633. [PMID: 29983275 DOI: 10.1016/j.ejso.2018.01.082] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
295 Owen DH, Alexander AJ, Konda B, Wei L, Hemminger JA, Schmidt CR, Abdel-Misih SRZ, Dillhoff ME, Sipos JA, Kirschner LS, Shah MH. Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response. Oncotarget 2017;8:104046-56. [PMID: 29262620 DOI: 10.18632/oncotarget.22001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
296 Lu L, Shang Y, Mullins CS, Zhang X, Linnebacher M. Epidemiologic trends and prognostic risk factors of patients with pancreatic neuroendocrine neoplasms in the US: an updated population-based study. Future Oncol 2021;17:549-63. [PMID: 33401958 DOI: 10.2217/fon-2020-0543] [Reference Citation Analysis]
297 Scott AT, Howe JR. Management of Small Bowel Neuroendocrine Tumors. J Oncol Pract. 2018;14: 471-482. [PMID: 30096273 DOI: 10.1200/jop.18.00135] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
298 Zheng-Pywell R, Fang A, AlKashash A, Awad S, Reddy S, Vickers S, Heslin M, Dudeja V, Chen H, Rose JB. Prognostic Impact of Tumor Size on Pancreatic Neuroendocrine Tumor Recurrence May Have Racial Variance. Pancreas 2021;50:347-52. [PMID: 33835965 DOI: 10.1097/MPA.0000000000001776] [Reference Citation Analysis]
299 Singh S, Bergsland EK, Card CM, Hope TA, Kunz PL, Laidley DT, Lawrence B, Leyden S, Metz DC, Michael M, Modahl LE, Myrehaug S, Padda SK, Pommier RF, Ramirez RA, Soulen M, Strosberg J, Sung A, Thawer A, Wei B, Xu B, Segelov E. Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. J Thorac Oncol. 2020;15:1577-1598. [PMID: 32663527 DOI: 10.1016/j.jtho.2020.06.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
300 Chang JS, Chen LT, Shan YS, Chu PY, Tsai CR, Tsai HJ. An updated analysis of the epidemiologic trends of neuroendocrine tumors in Taiwan. Sci Rep 2021;11:7881. [PMID: 33846396 DOI: 10.1038/s41598-021-86839-2] [Reference Citation Analysis]
301 Wu J, Sun C, Li E, Wang J, He X, Yuan R, Yi C, Liao W, Wu L. Non-functional pancreatic neuroendocrine tumours: emerging trends in incidence and mortality. BMC Cancer 2019;19:334. [PMID: 30961556 DOI: 10.1186/s12885-019-5543-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]